<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02579564</url>
  </required_header>
  <id_info>
    <org_study_id>CTAEMTF</org_study_id>
    <nct_id>NCT02579564</nct_id>
  </id_info>
  <brief_title>Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients</brief_title>
  <official_title>Systemic Chemotherapy Combined With Thoracic Cavity Perfusion of Recombinant Human Adenovirus Type 5 and Endostatin Injections Versus Cisplatin for Treatment Malignant Hydrothorax in Non Small Cell Lung Cancer (NSCLC) Patients: A Multi-center, Randomized, Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinqiao Hospital of Chongqing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this multi-center clinical trial is to verify more effective on local control
      of malignant pleural effusions in NSCLC patients by thoracic cavity perfusion of recombinant
      human adenovirus type 5 injection and recombinant human Endostatin injection (Endostar)
      compared with cisplatin perfusion, with acceptable side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Malignant pleural effusion, which can malfunction of circulatory and respiratory systems, is
      a common complication in advanced NSCLC, finally decreases the quality of life and lifespan.
      Nowadays, it is still a challenge to effectively control malignant pleural effusion. In this
      multi-center randomized and controlled clinical trial, 134 NSCLC patients diagnosed as
      malignant pleural effusion in the first time will enroll. Based on systemic chemotherapy and
      pleural cavity perfusion, all eligible patients are randomly assigned into treatment group
      (recombinant human adenovirus type 5 and Endostatin injections) and control group (cisplatin)
      with ratio 1:1. Local control rate and side effects are record respectively. The anticipation
      is that treatment group obtains faster and longer control of pleural effusion.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) of malignant pleural effusions</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Assessed by WHO Cancerous effusion scoring system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>quality of life</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Assessed by Karnofsky Performance Status(KPS)</description>
  </other_outcome>
  <other_outcome>
    <measure>side effects</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Assessed by NCI CTC3.0</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Malignant Hydrothorax</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>chemotherapy with Oncorine and Endostar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Systemic chemotherapy with standard schemes, such as GP (Gemcitabine/Cisplatin), NP (Vinorelbine/Cisplatin), TP (Paclitaxel/Cisplatin) or PP (Pemetrexed/Cisplatin). Thoracic cavity perfusion of recombinant human adenovirus type 5 injection 1.5ml and Endostar 30mg each time, twice a week for four times.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy with cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Systemic chemotherapy with standard schemes without cisplatin, such as Gemcitabine, Vinorelbine, Paclitaxel or Pemetrexed. Thoracic cavity perfusion of cisplatin 30mg/m2 each time, twice a week for four times.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>chemotherapy with Oncorine and Endostar</arm_group_label>
    <arm_group_label>chemotherapy with cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <arm_group_label>chemotherapy with Oncorine and Endostar</arm_group_label>
    <arm_group_label>chemotherapy with cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>chemotherapy with Oncorine and Endostar</arm_group_label>
    <arm_group_label>chemotherapy with cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <arm_group_label>chemotherapy with Oncorine and Endostar</arm_group_label>
    <arm_group_label>chemotherapy with cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oncorine</intervention_name>
    <arm_group_label>chemotherapy with Oncorine and Endostar</arm_group_label>
    <other_name>recombinant human adenovirus type 5 injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostar</intervention_name>
    <arm_group_label>chemotherapy with Oncorine and Endostar</arm_group_label>
    <other_name>recombinant human endostatin injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>chemotherapy with Oncorine and Endostar</arm_group_label>
    <arm_group_label>chemotherapy with cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age 18-75 yrs;

          2. Kamofsky score (KPS) â‰¥70, and a predicted lifespan &gt;3 months;

          3. Enough function of vital organs, such as heart, liver and kidney;

          4. Advanced NSCLC diagnosed by cytology or pathology

          5. Unilateral or bilateral of malignant pleural effusion in the first time;

          6. Patients who are considered as malignant pleural effusion by cytology or biomarkers
             (CEA, CA199, CA125) in pleural effusion;

          7. Without systemic infection or high fever;

          8. Without active EGFR mutation or unwilling to targeted molecular therapy;

          9. NO Anti tumor Radiotherapy chemotherapy and molecular targeted therapy,or Received
             Anti tumor Radiotherapy chemotherapy and molecular and clinical remission more than
             three months and in the past month ,disease progress with pleural cavity effusion but
             haven't use systemic or local anti tumor treatment.

         10. No pleural cavity injection of antineoplastic drugs.

        Exclusion Criteria:

          1. Non-malignant pleural effusion;

          2. Pleural effusion cause by other malignant tumors;

          3. Allergic to Recombinant human adenovirus type 5 injection or Endostar;

          4. Pregnant or lactation women;

          5. Previously using Medicine for treating NSCLC with pleural cavity effusion by Systemic
             or pleural cavity perfusion treatment one month prior to enrollment;

          6. Previously using the diuretics, albumin and anti-angiogenesis drugs, or dexamethasone
             one month prior to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ZhengTang Chen, PHD</last_name>
    <phone>+862368755625</phone>
    <email>1240887467@qq.com</email>
  </overall_contact>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>October 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2015</study_first_posted>
  <last_update_submitted>October 20, 2016</last_update_submitted>
  <last_update_submitted_qc>October 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinqiao Hospital of Chongqing</investigator_affiliation>
    <investigator_full_name>Zhengtang Chen</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Hydrothorax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

